sickle cell disease

Showing 7 posts of 7 posts found.


FDA halts studies for bluebird bio’s sickle cell therapy LentiGlobin

February 24, 2021
Research and Development Bluebird Bio, FDA, sickle cell disease

The FDA has put bluebird bio’s LentiGlobin gene therapy programme for sickle cell disease (SCD) on clinical hold, following Suspected …

Novartis and Gates Foundation join forces on sickle cell disease research

February 17, 2021
Research and Development Novartis, sickle cell disease

Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation, under which the foundation will fund …


FDA approves GBT’s Oxbryta to treat sickle cell disease

November 26, 2019
Manufacturing and Production FDA, FDA Trump, Oxbryta, Sickle cell, sickle cell disease

The FDA announced yesterday that it has approved Global Blood Therapeutics’ marketing application for its haemoglobin polymerisation inhibitor Oxbryta, which …

Novartis’ Adakveo becomes first FDA-approved P-selectin inhibitor for sickle cell disease

November 18, 2019
Sales and Marketing Adakve, Novartis, pharma, sickle cell disease

The FDA has chosen to award Novartis’ Adakveo (crizanlizumab) with marketing authorisation, it has emerged, as a treatment to reduce …


Novartis’ sickle cell drug reduces vaso-occlusive crises by 35% at Phase 2

October 10, 2018
Research and Development Novartis, crizanlizumab, pharma, sickle cell disease

Novartis has presented new Phase 2 data for its humanised anti-P-selectin monoclonal antibody crizanlizumab in the treatment of sickle cell …


FDA gives go-ahead to first sickle cell treatment in 20 years

July 10, 2017
Sales and Marketing Emmaus Medical, L-glutamine, sickle cell disease

Emmaus Medical has been handed approval for the first new treatment for sickle cell disease in two decades. The active …


Shares in Global Blood jump after positive results for trial sickle cell drug

June 13, 2016
Research and Development, Sales and Marketing Global Blood Therapeutics, drug trial, sickle cell disease

Global Blood Therapeutics (Nasdaq: GBT) shares jumped to close up over 9% Friday after the company said its trial drug …

Latest content